Edition:
United Kingdom

Seikagaku Corp (4548.T)

4548.T on Tokyo Stock Exchange

1,829JPY
24 Apr 2018
Change (% chg)

-- (--)
Prev Close
¥1,829
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
187,353
52-wk High
¥2,236
52-wk Low
¥1,535

Latest Key Developments (Source: Significant Developments)

Seikagaku initiates a phase III clinical trial (additional study) in the U.S. for SI-6603
Monday, 19 Feb 2018 

Feb 19 (Reuters) - Seikagaku Corp <4548.T>:Says it will initiate a Phase III clinical trial (additional study) in the U.S. for SI-6603, indicated for the treatment of radicular leg pain (i.e. sciatica) due to a lumbar disc herniation. .  Full Article

Ribomic signs collaborative research contract with SEIKAGAKU
Wednesday, 8 Nov 2017 

Nov 8 (Reuters) - Ribomic Inc <4591.T>:Says it signed collaborative research contract with SEIKAGAKU CORPORATION <<<4548.T>>>.Says two entities mainly cooperate on new technologies development of drug discovery related to Aptamers.  Full Article

Seikagaku signs exclusive worldwide license agreement for treatment for lumbar disc herniation
Monday, 29 Aug 2016 

Seikagaku Corporation <4548.T>: Says the co entered into an exclusive worldwide license agreement(excluding Japan) with Ferring Pharmaceuticals for SI-6603(condoliase), a potential treatment for lumbar disc herniation .Says the co will receive an upfront payment of $5 million and milestone payments up to a maximum total amount of $90 million over multiple years upon future progress in development and commercialization.  Full Article

Seikagaku signs agreement for license of lumbar disc herniation treatment agent with Ferring Pharmaceuticals
Wednesday, 15 Jun 2016 

Seikagaku <4548.T>:Says it signed an agreement for overseas exclusive sale license of lumbar disc herniation treatment agent with Ferring Pharmaceuticals.  Full Article

Seikagaku to retire 1,770,000 treasury shares
Thursday, 12 May 2016 

Seikagaku <4548.T>: Says it to retire 1,770,000 shares (3 pct stake) of its common stock on May 31 .Says the total shares outstanding will be 56,814,093 shares after the retirement.  Full Article

BRIEF-Seikagaku announces new drug application approval of hernicore® 1.25 units for intradiscal injection in Japan

* Says it announced that the Japanese Ministry of Health, Labour and Welfare has approved the new drug application of HERNICORE® 1.25 units for intradiscal injection in Japan, indicated for the treatment of lumbar disc herniation